Dallas, Texas 02/13/2014 (FINANCIALSTRENDS) – Housed in Cambridge, MA, Zalicus Inc (NASDAQ:ZLCS) bio pharmaceutics focuses on the development and discovery of drugs for pain management and for treating of diseases related to immuno- inflammation. It’s main product is Zalicus, and in November results of the Phase 2 clinical trials for Z160, related to Chronic Neuropathic Pain were released. The report noted that Z160 had failed to meet requirements.
The company is now concentrating on the use of Z944 and is expected to release results soon.
Z160 program Phase 2 dismissed
Zalicus Inc (NASDAQ:ZLCS) had developed the N-type calcium blocker Z160 for selective use. The top-line results for the Phase 2 twin studies for lumbosacral radioculopathy as well as post-herpetic neuralgia revealed that the drug failed to meet the primary endpoint.
Zalicus Inc (NASDAQ:ZLCS) had in fact received a good preclinical profile for Z160 but was unable to translate it to clinical efficacy, explained the CEO of the biopharmaceutical company, Mark Corrigan.
Zalicus Inc (NASDAQ:ZLCS) has now completely dismissed further work on the Z160 program, has been a massive disappointment for patients suffering chronic pain as they had hopes pinned on this drug following the successful pre-clinical trials.
Collaboration in the pipeline
Zalicus Inc (NASDAQ:ZLCS) has also announced products and candidates in collaboration with big-sized pharmaceutical companies. The company has since discovered and developed selective ion channel modulators as well as combination throughput screening technology called as cHTSTM. This is expected to help in the discovery of new product candidates as well as collaborators, related to pain, oncology as well as inflammation, infectious disease treatments as well.
Zalicus Inc (NASDAQ:ZLCS) expects the new collaborations to generate higher revenue. The biopharmaceutical is currently holds market value of $36.79 million, and average volume of 1.87 million. The stock prices for the company are at $1.41 with historic 52 week high of $8.28 and low of $0.88. EPS for the share is -1.72 and Beta 1.77.